TNFAIP8 overexpression is associated with platinum resistance in epithelial ovarian cancers with optimal cytoreduction

Human Pathology

Volumn 45, Issue 6, 2014, Pages 1251-1257

  Liu, Tianbo ^a   Xia, Bairong ^a   Lu, Yanhong ^b   Xu, Ye ^a   Lou, Ge ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Heilongjiang Province Hospital   (China)

Author keywords

Epithelial ovarian cancer; Optimal cytoreduction; Platinum resistance; Tumor necrosis factor induced protein 8

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; DOCETAXEL; MESSENGER RNA; PACLITAXEL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 8; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASCITES; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CANCER SUSCEPTIBILITY; CYTOREDUCTIVE SURGERY; DISEASE ASSOCIATION; DRUG SENSITIVITY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; REAL TIME POLYMERASE CHAIN REACTION; TUMOR VOLUME; WESTERN BLOTTING;

EPITHELIAL OVARIAN CANCER; OPTIMAL CYTOREDUCTION; PLATINUM RESISTANCE; TUMOR NECROSIS FACTOR Α-INDUCED PROTEIN 8;

ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UP-REGULATION;

EID: 84901394890     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2014.02.005     Document Type: Article

References (35)

1. D. Kumar, T.L. Whiteside, and U. Kasid Identification of a novel tumor necrosis factor-alpha-inducible gene, SCC-S2, containing the consensus sequence of a death effector domain of fas-associated death domain-like interleukin-1beta-converting enzyme-inhibitory protein J Biol Chem 275 2000 2973 2978
2. A.J. Horrevoets, R.D. Fontijn, A.J. van Zonneveld, C.J. de Vries, J.W. ten Cate, and H. Pannekoek Vascular endothelial genes that are responsive to tumor necrosis factor-alpha in vitro are expressed in atherosclerotic lesions, including inhibitor of apoptosis protein-1, stannin, and two novel genes Blood 93 1999 3418 3431
3. Z. You, H. Ouyang, D. Lopatin, P.J. Polver, and C.Y. Wang Nuclear factor-kappa B-inducible death effector domain-containing protein suppresses tumor necrosis factor-mediated apoptosis by inhibiting caspase-8 activity J Biol Chem 276 2001 26398 26404
4. D. Kumar, P. Gokhale, C. Broustas, D. Chakravarty, I. Ahmad, and U. Kasid Expression of SCC-S2, an antiapoptotic molecule, correlates with enhanced proliferation and tumorigenicity of MDA-MB 435 cells Oncogene 23 2004 612 616
5. C. Zhang, D. Chakravarty, and I. Sakabe et al. Role of SCC-S2 in experimental metastasis and modulation of VEGFR-2, MMP-1, and MMP-9 expression Mol Ther 13 2006 947 955
6. K. Liu, C.K. Qin, Z.Y. Wang, S.X. Liu, X.P. Cui, and D.Y. Zhang Expression of tumor necrosis factor-alpha-induced protein 8 in pancreas tissues and its correlation with epithelial growth factor receptor levels Asian Pac J Cancer Prev 13 2012 847 850
7. Z. Miao, T. Zhao, and Z. Wang SCC-S2 is overexpressed in colon cancers and regulates cell proliferation Tumour Biol 33 2012 2099 2106
8. C. Zhang, B.V. Kallakury, and J.S. Ross et al. The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence Int J Cancer 133 2012 31 42
9. T.Y. Shi, X. Cheng, and K.D. Yu et al. Functional variants in TNFAIP8 associated with cervical cancer susceptibility and clinical outcomes Carcinogenesis 34 2013 770 778
10. Q.Z. Dong, Y. Zhao, and Y. Liu et al. Overexpression of SCC-S2 correlates with lymph node metastasis and poor prognosis in patients with non-small-cell lung cancer Cancer Sci 101 2010 1562 1569
11. Y.E. Hadisaputri, T. Miyazaki, and S. Suzuki et al. TNFAIP8 overexpression: clinical relevance to esophageal squamous cell carcinoma Ann Surg Oncol 19 2012 S589 S596
12. Y. Zhang, M.Y. Wang, and J. He et al. Tumor necrosis factor-α induced protein 8 polymorphism and risk of non-Hodgkin's lymphoma in a Chinese population: a case-control study PLoS One 7 2012 e37846
13. T. Liu, H. Gao, and X. Chen et al. TNFAIP8 as a predictor of metastasis and a novel prognostic biomarker in patients with epithelial ovarian cancer Br J Cancer 109 2013 1685 1692
14. M.C. Wang, S.X. Liu, and P.B. Liu Gene expression profile of multiple myeloma cell line treated by realgar J Exp Clin Cancer Res 25 2006 243 249
15. R.F. Ozols Treatment goals in ovarian cancer Int J Gynecol Cancer 15 2005 3 11
16. E.E. Partridge, and M.N. Barnes Epithelial ovarian cancer: prevention, diagnosis, and treatment CA Cancer J Clin 49 1999 297 320
17. V. Guarneri, F. Piacentini, E. Barbieri, and P.F. Conte Achievements and unmet needs in the management of advanced ovarian cancer Gynecol Oncol 117 2010 152 158
18. R. Agarwal, and S.B. Kaye Ovarian cancer: strategies for overcoming resistance to chemotherapy Nat Rev Cancer 3 2003 502 516
19. H. Kobayashi, Y. Yamada, and S. Kanayama et al. The role of hepatocyte nuclear factor-1beta in the pathogenesis of clear cell carcinoma of the ovary Int J Gynecol Cancer 19 2009 471 479
20. F.A. Tavassoeli, and P. Devilee WHO Classification of tumours, pathology and genetics: tumours of the breast and female genital organs 2003 IARC Lyon
21. J.L. Benedet, H. Bender, H. Jones 3rd, H.Y. Ngan, and S. Pecorelli FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology Int J Gynaecol Obstet 70 2000 209 262
22. R.F. Ozols, B.N. Bundy, and B.E. Greer et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 2003 3194 3200
23. Morgan RJ, Alvarez RD, Armstrong DK, et al. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. NCCN clinical practice guidelines in oncology. 2009.
24. M. Markman, and M.A. Bookman Second-line treatment of ovarian cancer Oncologist 5 2000 26 35
25. K.J. Livak, and T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method Methods 25 2001 402 408
26. S. Patel, F.H. Wang, T.L. Whiteside, and U. Kasid Identification of seven differentially displayed transcripts in human primary and matched metastatic head and neck squamous cell carcinoma cell lines: implications in metastasis and/or radiation response Oral Oncol 33 1997 197 203
27. B. Laliberté, A.M. Wilson, and H. Nafisi et al. TNFAIP8: a new effector for Galpha(i) coupling to reduce cell death and induce cell transformation J Cell Physiol 225 2010 865 874
28. L.J. Zhang, X. Liu, P.R. Gafken, C. Kioussi, and M. Leid A chicken ovalbumin upstream promoter transcription factor I (COUP-TFI) complex represses expression of the gene encoding tumor necrosis factor alpha-induced protein 8 (TNFAIP8) J Biol Chem 284 2009 6156 6168
29. C.H. Holschneider, and J.S. Berek Ovarian cancer: epidemiology, biology, and prognostic factors Semin Surg Oncol 19 2000 3 10
30. D.S. Miller, J.A. Blessing, and C.N. Krasner et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group J Clin Oncol 27 2009 2686 2691
31. R.E. Bristow, R.S. Tomacruz, D.K. Armstrong, E.L. Trimble, and F.J. Montz Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol 20 2002 1248 1259
32. N. Ahmed, C. Riley, K. Oliva, G. Rice, and M. Quinn Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma Br J Cancer 92 2005 1475 1485
33. D. Lane, V. Robert, R. Grondin, C. Rancourt, and A. Piché Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells Int J Cancer 121 2007 1227 1237
34. E.L. Eisenhauer, N.R. Abu-Rustum, Y. Sonoda, C. Aghajanian, R.R. Barakat, and D.S. Chi The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer Gynecol Oncol 108 2008 276 281
35. R.E. Bristow, E.L. Eisenhauer, A. Santillan, and D.S. Chi Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction Gynecol Oncol 104 2007 480 490